Sign inJoin waitlistJoin the waitlist

Dwight Owen

Physician · Ohio State University College of Medicine

Credentials: · · · · · · ·

History

Ohio State University College of Medicine
Present

Hematology and Medical Oncology
2014–2017
Memorial Sloan Kettering Cancer Center
2011–2014
Doctor of Medicine
2006–2010

Research

Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024 · 922 citations
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
JAMA Oncology · 2020 · 397 citations
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Journal of Clinical Oncology · 2017 · 300 citations

GO
Gregory Otterson
37 papers
Carolyn Presley
36 papers
David Carbone
34 papers
Mingjia Li
31 papers
KH
Kai He
21 papers
Peter Shields
19 papers
EB
Erin Bertino
16 papers
KK
Kari Kendra
16 papers
Sandipkumar Patel
16 papers
Abdul Naqash
14 papers · 5 as a fellow
Asrar Alahmadi
14 papers · 1 as a fellow
Andrew Johns
13 papers · 12 as a resident

Grants

OSU as a Network Lead Academic Participating Site for the NCI NCTN
National Cancer Institute · UG1
PI · $1.1M · Ohio State University
2019–2032
Clinical Trial Concept in the Oncology Landscape
National Cancer Institute · R25
PI · $894.6K · Ohio State University
2024–2029
Cachexia-Mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer
National Cancer Institute · R01
PI · $3.1M · Ohio State University
2022–2027
Targeting Tumor-Associated Macrophages via Hedgehog Inhibition to Enhance Immunotherapy in Non-Small Cell Lung Cancer
National Cancer Institute · R21
Contact PI · $419.2K · Ohio State University
2025–2027

Clinical trials

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2025–2028
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Principal investigator · Suspended · Phase 1
Dwight Owen
2024–2027
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 1
Dwight Owen
2022–2026
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 2
Dwight Owen
2022–2028